Download Now: Precision May Events Calendar
The MayEvents Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Download Now: Precision April Events Calendar
The April Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study
Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. Precision's Jenny Chen, Sam Keeping and Julie Park joined other experts to conduct a large, retrospective chart review of European patients with R/R MCL with prior BTKi therapy (SCHOLAR-2).
QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)
Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.
De-risking Market Launch: Leveraging HEOR Evidence Planning to Support Informed Payer Decisions
HEOR data can help to close knowledge gaps and uncertainties that payers may possess when making decisions involving access and reimbursement. Precision's Jacquelyn Chou, Alexandria Portelli and Andrew Cournoyer discuss important steps in prelaunch HEOR planning to support a successful market launch.
PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT
BETHESDA, MD (January 26, 2023) Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.
Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts
Congratulations to Precision's Iver Jensen for his contributions to "Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome," a study recently published in the Journal of Pediatric Pharmacology and Therapeutics. The study is the first cost-consequence analysis cost-consequence analysis comparing the clinical and health economic outcomes in newborns with RDS when using selective early surfactant treatment vs standard surfactant administration in the United States.
Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome
Congratulations to Precision's Iver Jensen for his contributions to "Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome," a study recently published in the Journal of Pediatric Pharmacology and Therapeutics. The study is the first cost-consequence analysis cost-consequence analysis comparing the clinical and health economic outcomes in newborns with RDS when using selective early surfactant treatment vs standard surfactant administration in the United States.
Emerging Threats to Health Equity
Policy changes that expanded enrollment in Medicaid and Health Exchange plans are at risk. Precision's Cynthia Miller and Maureen Hennessey discuss why discontinuing the policy changes will contribute to health inequities in myriad ways, and identify the essential role pharmaceutical companies can play in mitigating the impact.
Progression-free survival and quality of life in metastatic breast cancer: The patient perspective
While treatment advances have improved overall survival in some metastatic breast cancer (mBC) subtypes, there remains no cure for mBC. Considering the use of progression-free survival and other surrogate endpoints in clinical trials, it's useful to understand patient perspectives on measures used to assess treatment efficacy. Precision's Suepattra May-Slater co-authored an important paper exploring global patient perceptions and their potential relation to quality of life, identifying considerations for the design and conduct of future clinical trials in mBC, as well as HTA and reimbursement decision-making, to better capture the potential value of a therapeutic innovation.
